The Fellow on Call: The Heme/Onc Podcast cover image

Episode 097: Treatment of Relapsed/Refractory CLL

The Fellow on Call: The Heme/Onc Podcast

00:00

Navigating Toxic Therapies and Poor Prognoses in CLL

This chapter examines the withdrawal of idelalisib from the market due to safety issues and its ineffectiveness compared to standard therapies for CLL. It highlights the critical nature of Richter's transformation in CLL and the increasing importance of patient preferences and MRD-guided treatment approaches.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app